Starting Colonoscopy Every 10 Years at Age 45 Cost-Effective for All
For all BMI/sex groups, initiating colonoscopy at 45 or annual FIT at 40 years is cost-effective at threshold of $100,000/QALY
Colorectal And Other GI Cancers
Cancer Risk Higher for Men vs Women at Most Shared Anatomic Sites
The proportion of excess cancer risk in men that was explained by risk factors was modest, ranging from 50 to 11 percent
Pembrolizumab Combos Miss Primary Endpoints in Liver, Prostate Cancer Trials
The LEAP-002 study evaluated pembrolizumab plus lenvatinib in patients with uHCC; the KEYNOTE-921 study evaluated pembrolizumab plus docetaxel in patients with mCRPC.
AbbVie Seeks Crohn Disease Indication for Upadacitinib
The application is supported by data from the two phase 3 induction studies, U-EXCEED and U-EXCEL, and one phase 3 maintenance study, U-ENDURE.
Prevalence of CRC Screening Remains Low in Those Aged 50 to 54
Increase in screening differed by age, with 19.4 percent increase for those aged 50 to 54 and 31.6 percent increase for those aged 70 to 75
Skyrizi Approved for Moderately to Severely Active Crohn Disease
The approval was based on data from two phase 3 induction studies, and one phase 3 maintenance study.
May 2022: Drug Pipeline Updates
Stay up-to-date on the latest drugs in development.
Opdivo-Based Regimens Approved as First-Line Treatments for Esophageal Cancer
The approvals are based on data from the phase 3 CheckMate-648 trial, which included 970 adults with previously untreated unresectable advanced, recurrent or metastatic ESCC.
Upadacitinib Meets Endpoints in Crohn Disease Maintenance Trial
The phase 3 U-ENDURE study included adults with moderate to severe Crohn disease who responded to upadacitinib induction treatment.
Colonoscopy Before Age 50 May Cut Colorectal Cancer Risk in Women
Reduced risk seen with earlier initiation of endoscopy, including lower risk for colorectal cancer diagnosed in women before 55 years of age
